엠팍스 검사 시장 : 기술, 모드, 최종 용도별 - 세계 예측(2024-2032)

The Monkeypox Testing Market will record 4.5% CAGR during 2024 and 2032, driven by the increasing incidences of monkeypox outbreaks. In May 2024, WHO reported 646 new laboratory-confirmed cases of monkeypox and 15 deaths across 26 countries. Lately, there has been a resurgence of monkeypox cases in various regions, including areas previously considered low risk. This has underscored the urgent need for effective and timely diagnostic solutions to manage and control outbreaks, boosting the demand for testing kits.

Governments, healthcare organizations, and public health authorities are prioritizing the development and implementation of comprehensive strategies to manage and control infectious diseases, including monkeypox. This heightened focus is driven by the growing need for effective surveillance and response mechanisms. Investments in healthcare infrastructure, enhanced diagnostic capabilities, and the establishment of robust disease management protocols are all contributing to the industry growth.

The monkeypox testing industry is classified based on technology, mode, end-use, and region.

The Polymerase Chain Reaction segment will gain traction through 2032, as PCR is a highly sensitive and specific method used to detect the genetic material of the monkeypox virus, enabling early and accurate diagnosis. The technology's ability to amplify minute quantities of viral DNA makes it an indispensable tool in diagnosing monkeypox infections. PCR-based tests are preferred for their high accuracy and reliability, which are crucial for effective disease management and control.

Diagnostic laboratories segment share will grow steadily during 2024 and 2032, as these laboratories are responsible for conducting monkeypox tests and providing accurate results to healthcare providers. The increasing number of diagnostic laboratories equipped with advanced testing technologies is driving the demand for monkeypox testing solutions. Additionally, the expansion of medical facilities and the growing focus on infectious disease management are contributing to the rise in demand for monkeypox testing services.

Asia Pacific monkeypox testing industry will expand at a fast pace through 2032, due to the increasing awareness and implementation of advanced diagnostic technologies. Countries in the region are enhancing their healthcare infrastructure and investing in state-of-the-art testing facilities to combat infectious diseases. There is rising awareness about monkeypox and need for early detection for proper management of the disease. Additionally, regional governments and health organizations are prioritizing disease surveillance and outbreak management, further boosting the demand for monkeypox testing solutions.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of monkeypox cases
    • 3.2.1.2 Increasing awareness among the population
    • 3.2.1.3 Advancements in diagnostic research
    • 3.2.1.4 Rising government funding and initiatives
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost of testing
    • 3.2.2.2 Stringent regulatory challenges
• 3.3 Technological landscape
• 3.4 Regulatory landscape
• 3.5 Porter's analysis
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Competitive positioning matrix
• 4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Technology, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Polymerase chain reaction (PCR)
• 5.3 Lateral flow assay (LFA)
• 5.4 Other technologies

Chapter 6 Market Estimates and Forecast, By Mode, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Laboratory testing
• 6.3 Point of care testing

Chapter 7 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals and clinics
• 7.3 Diagnostic laboratories
• 7.4 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 South Africa
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Abbott Laboratories
• 9.2 Aegis Sciences Corporation
• 9.3 Applied DNA Sciences, Inc.
• 9.4 Becton, Dickinson and Company
• 9.5 BioGX
• 9.6 bioMerieux SA
• 9.7 Bio-Rad Laboratories, Inc.
• 9.8 CerTest Biotec
• 9.9 Creative Biogene
• 9.10 Danaher Corporation
• 9.11 Flow Health
• 9.12 Laboratory Corporation of America Holdings
• 9.13 Mayo Clinic Laboratories
• 9.14 Quest Diagnostics, Inc.
• 9.15 Thermo Fisher Scientific Inc.